Retinnovate 2025: Equipping Retinal Disease Innovators for Market Success
| November 13th – 14th
|
Overview: We’re excited to share that Paul Ryb, Managing Director at Outcome Capital, will be speaking at Retinnovate 2025: Equipping Retinal Disease Innovators for Market Success, taking place November 13–14 at Riddell Hall, Queen’s University Belfast.Paul will present on the UK ophthalmic innovation landscape, focusing on the critical gap between early-stage breakthroughs and the funding pathways required to bring them to market. Drawing from Outcome Capital’s deep sector knowledge, he’ll address how innovators can bridge the space between grant funding and the capital needed to achieve both patient impact and investor returns.This is an essential session for researchers, founders, and investors working at the intersection of eye health and innovation commercialization. Learn more and register: https://www.flowcoevents.com/retinnovate #Retinnovate2025 #Ophthalmology #MedTech #LifeSciences #OutcomeCapital #HealthcareInnovation #VentureFunding #StartupGrowth #InvestmentBanking #RetinalDisease #EyeHealth #UKInnovation #TechTransfer |
News
Outcome Capital Named Top Life Sciences Advisory and Strategic Investment Banking Solutions Provider for 2026
Outcome Capital has been named Life Sciences Review’s exclusive recipient of the “Top Life Sciences Advisory and Strategic Investment Banking Solutions 2026” award, recognizing its unique approach to helping life sciences companies move innovations from development to commercialization. The firm combines scientific, clinical, operational, and financial expertise to support emerging and growth-stage companies with fundraising, […]
Read MoreResources
Outcome Capital Life Science Pulse
Outcome Capital Life Science Market Pulse June 2026 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2026. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
